IMGN News and Press, ImmunoGen Inc. From 11/01/23

2023-11-01 12:52:35 ET More on ImmunoGen Analyzing The Acquisition Potential Of ImmunoGen ImmunoGen: Takeda Swoops For Slice Of Elahere - Adding To Valuation Uncertainty? ImmunoGen Stock Falls, Elahere Growth Contrasts (Rating Upgrade) ImmunoGen's ovarian can...

2023-10-31 15:25:10 ET Summary ImmunoGen, Inc.'s marketing authorization application for ELAHERE, a cancer therapy, has been accepted by the EMA. Rumors suggest that large European pharma companies, including GSK, Sanofi, or Merck, may be interested in ImmunoGen. ImmunoGen has...

2023-10-27 07:38:20 ET The European Medicines Agency (EMA) has accepted marketing authorization application for ImmunoGen's ( NASDAQ: IMGN ) cancer medication. The agency accepted ImmunoGen's ( IMGN ) marketing authorization application for ELAHERE (mirvetuximab soravtan...

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for mirvetuximab soravtansine (ELAHERE ® )...

2023-10-24 12:56:21 ET More on ImmunoGen ImmunoGen: Takeda Swoops For Slice Of Elahere - Adding To Valuation Uncertainty? ImmunoGen Stock Falls, Elahere Growth Contrasts (Rating Upgrade) ImmunoGen, Inc. (IMGN) Q2 2023 Earnings Call Transcript ImmunoGen draws ...

Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board PR Newswire SAN JOSE, Calif. , Oct. 23, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NA...

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Thursday, November 2, 2023 to discuss its third quarter 2023 operating results. Manageme...

2023-10-06 13:54:23 ET More on ImmunoGen ImmunoGen: Takeda Swoops For Slice Of Elahere - Adding To Valuation Uncertainty? ImmunoGen Stock Falls, Elahere Growth Contrasts (Rating Upgrade) ImmunoGen, Inc. (IMGN) Q2 2023 Earnings Call Transcript ImmunoGen appoin...

2023-10-06 12:20:23 ET More on Sutro Biopharma Sutro BioPharma: Good Stewardship Through Early Trials Seeking Alpha’s Quant Rating on Sutro Biopharma Historical earnings data for Sutro Biopharma Financial information for Sutro Biopharma For fur...

Data Further Position ELAHERE to Become the New Standard of Care for Patients with FRα-Positive Platinum-Resistant Ovarian Cancer Findings to be Highlighted in Oral Presentation at ESGO Annual Congress ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of ...